申请人:Kylonova (Xiamen) Biopharma Co., Ltd.
公开号:EP3992291A1
公开(公告)日:2022-05-04
The present invention relates to a novel compound and application thereof in the inhibition of HBV gene expression. The structure of the compound comprises an interfering nucleic acid for inhibiting HBV gene expression, transition points, and delivery chains of the interfering nucleic acid. By means of the delivery chains, two or three N-acetylgalactosamines can be introduced to an antisense strand 3' end of such siRNA, and two or one N-acetylgalactosamine can be correspondingly introduced to a sense strand 5' end, the total number of the introduced N-acetylgalactosamines being four. In vitro and in vivo pharmacological experiments prove that such a novel compound can continuously and efficiently inhibit HBV gene expression.
本发明涉及一种新型化合物及其在抑制 HBV 基因表达中的应用。该化合物的结构包括用于抑制 HBV 基因表达的干扰核酸、过渡点和干扰核酸的输送链。通过输送链,可以在这种 siRNA 的反义链 3' 端引入两个或三个 N-乙酰半乳糖胺,在义链 5' 端相应地引入两个或一个 N-乙酰半乳糖胺,引入的 N-乙酰半乳糖胺总数为四个。体外和体内药理实验证明,这种新型化合物可以持续有效地抑制 HBV 基因的表达。